Neurocrine Biosciences (FRA:NB3) Ending Cash Position : €372 Mil (As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Neurocrine Biosciences Ending Cash Position?

Neurocrine Biosciences's Ending Cash Position for the quarter that ended in Mar. 2024 was €372 Mil.

Neurocrine Biosciences's quarterly Ending Cash Position declined from Sep. 2023 (€283 Mil) to Dec. 2023 (€238 Mil) but then increased from Dec. 2023 (€238 Mil) to Mar. 2024 (€372 Mil).

Neurocrine Biosciences's annual Ending Cash Position declined from Dec. 2021 (€304 Mil) to Dec. 2022 (€256 Mil) and declined from Dec. 2022 (€256 Mil) to Dec. 2023 (€238 Mil).

Neurocrine Biosciences Ending Cash Position Historical Data

The historical data trend for Neurocrine Biosciences's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurocrine Biosciences Ending Cash Position Chart

Neurocrine Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

103.95

156.43

304.44

255.54

237.60

Neurocrine Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial															104.23	155.25	282.69	237.60	371.96

Neurocrine Biosciences Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Neurocrine Biosciences's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	248.233	+	-10.638
	=	238

Neurocrine Biosciences's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	238.372	+	133.584
	=	372

Neurocrine Biosciences Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Neurocrine Biosciences's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurocrine Biosciences (FRA:NB3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (FRA:NB3) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

NBIX:USA N1BI34:Brazil

Address

12780 El Camino Real, San Diego, CA, USA, 92130

Website

https://www.neurocrine.com

Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Neurocrine Biosciences (FRA:NB3) Headlines

No Headlines